DAT (chemotherapy)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

DAT in the context of chemotherapy is an acronym that means a chemotherapy regimen most often used as an induction regimen in acute myelogenous leukemia, usually for those who are refractory to the standard "7+3" induction regimen or who has relapsed. But this regimen also can be used as primary, first-line induction therapy.

The DAT regimen consists of:

  1. (D)aunorubicin - an anthracycline antibiotic that is able to intercalate DNA, thus disrupting cell division and preventing mitosis;
  2. (A)ra-C (cytarabine) - an antimetabolite;
  3. (T)hioguanine - another antimetabolite.[1]

Dosing regimen[edit]

Drug Dose Mode Days
Ara-C (cytarabine) 200 mg/m2 IV push every 12 hours in 2 divided doses (100 mg/m2 each) Days 1-10
Daunorubicin 50 mg/m2 IV slow push Days 1, 3 and 5
Thioguanine 200 mg/m2 PO every 12 hours in 2 divided doses (100 mg/m2 each) Days 1-10

References[edit]